Heparin-induced thrombocytopenia

New England Journal of Medicine

Volumn 373, Issue 19, 2015, Pages 1882-1883

  Klarenbeek, Naomi B ^a   Eikenboom, Jeroen C J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; ANTITHROMBIN; HEPARIN; PIPECOLIC ACID DERIVATIVE;

DOSE RESPONSE; DRUG CHOICE; EVIDENCE BASED MEDICINE; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; LETTER; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOSIS; THROMBOSIS PREVENTION; CHEMICALLY INDUCED; FEMALE; THROMBOCYTOPENIA;

ANTITHROMBINS; FEMALE; HEPARIN; HUMANS; PIPECOLIC ACIDS; THROMBOCYTOPENIA;

EID: 84946553115     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1510993     Document Type: Letter

References (5)

1. Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med 2015;373: 252-61.
2. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001;85: 950-7.
3. Tardy-Poncet B, Tardy B, Reynaud J, et al. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-Associated thrombocytopenia. Chest 1999;115: 1616-20.
4. Schenk JF, Pindur G, Stephan B, et al. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2003;9: 25-32.
5. Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: A propensity score-matched study. Blood 2015;125: 924-9.